AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy
Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD
CompanyDrug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
CompanyDeals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices
Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities
Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound
CompanyDrug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere
CompanyDeals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche
CompanyDeals

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board
CompanyDeals

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio
CompanyDeals

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio

CSPC's ALMB-0166 Approved for Phase II Trials in Parkinson's Disease
Drug

CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial
CompanyDrug

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial